Skip to Main content Skip to Navigation
New interface
Journal articles

Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.

Julien Edeline 1, 2, * Cédric Coulouarn 1 Laurence Crouzet 2 Marc Pracht 3 Nicolas Lepareur 4, 1, 5 Bruno Clément 1 Etienne Garin 1 
* Corresponding author
4 Microenvironnement et remodelage
Foie, métabolismes et cancer, UEB - Université européenne de Bretagne - European University of Brittany
Abstract : Synergy between yttrium-90 ((90)Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI \textless 1 denoting synergy and CI \textgreater 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with (90)Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with (90)Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with (90)Y radioembolization for treatment of liver cancer.
Document type :
Journal articles
Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01237102
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Tuesday, May 31, 2016 - 9:27:39 AM
Last modification on : Wednesday, March 30, 2022 - 2:37:27 PM
Long-term archiving on: : Thursday, September 1, 2016 - 11:27:22 AM

File

Gemcitabine and Oxaliplatin bu...
Files produced by the author(s)

Identifiers

Citation

Julien Edeline, Cédric Coulouarn, Laurence Crouzet, Marc Pracht, Nicolas Lepareur, et al.. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.. JVIR: Journal of Vascular and Interventional Radiology, 2015, 26 (12), pp.1874--1878.e2. ⟨10.1016/j.jvir.2015.06.032⟩. ⟨hal-01237102⟩

Share

Metrics

Record views

336

Files downloads

356